Difference between revisions of "Soft tissue sarcoma - historical"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://www.thelancet.com/journals/lancet/article/PII" to "https://doi.org/10.1016/") |
Warner-admin (talk | contribs) m (Text replacement - "====Supportive medications" to "====Supportive therapy") |
||
| Line 44: | Line 44: | ||
'''21-day cycles''' | '''21-day cycles''' | ||
| − | ====Supportive | + | ====Supportive therapy==== |
*CP15-0806, optional: [[Dexrazoxane (Zinecard)]] (dose not specified) IV once on day 1 | *CP15-0806, optional: [[Dexrazoxane (Zinecard)]] (dose not specified) IV once on day 1 | ||
Revision as of 14:33, 6 October 2022
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main soft tissue sarcoma page for current regimens.
2 regimens on this page
4 variants on this page
|
Locally advanced or metastatic disease, combination regimens
Doxorubicin & Olaratumab
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Tap et al. 2016 (CP15-0806) | 2010-2013 | Randomized Phase 2 (E-RT-esc) | Doxorubicin | Superior OS |
| Tap et al. 2020 (ANNOUNCE) | 2015-2018 | Phase 3 (E-esc) | Doxorubicin | Did not meet primary endpoint of OS |
Chemotherapy
- Doxorubicin (Adriamycin) as follows:
- Cycles 1 to 8: 75 mg/m2 IV once on day 1
Targeted therapy
- Olaratumab (Lartruvo) 15 mg/kg IV once per day on days 1 & 8
21-day cycles
Supportive therapy
- CP15-0806, optional: Dexrazoxane (Zinecard) (dose not specified) IV once on day 1
References
- CP15-0806: Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30;388(10043):488-97. Epub 2016 Jun 9. Erratum in: Lancet. 2016 Jul 30;388(10043):464. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01185964
- ANNOUNCE: Tap WD, Wagner AJ, Schöffski P, Martin-Broto J, Krarup-Hansen A, Ganjoo KN, Yen CC, Abdul Razak AR, Spira A, Kawai A, Le Cesne A, Van Tine BA, Naito Y, Park SH, Fedenko A, Pápai Z, Soldatenkova V, Shahir A, Mo G, Wright J, Jones RL; ANNOUNCE Investigators. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. JAMA. 2020 Apr 7;323(13):1266-1276. link to original article link to PMC article PubMed NCT02451943